Eli Lilly and Company (NYSE:LLY) has announced that Philip Johnson, the group vice president and treasurer, will be retiring from the company after more than 28 years of service. His retirement is scheduled for the end of February, as he moves on to pursue new professional opportunities.
Anat Ashkenazi, the executive vice president and chief financial officer at Lilly, praised Johnson’s significant contributions over the years, citing his profound financial acumen, industry understanding, and dedication to Lilly’s mission and patients. Johnson has been instrumental in various leadership capacities within the company, demonstrating a commitment to talent development through extensive mentoring and coaching efforts worldwide.
During his tenure, Johnson has supported diverse operational aspects, including overseeing Lilly affiliates in Japan and Spain, global manufacturing, quality operations, and business development endeavors. Notably, he served as the head of Lilly’s investor relations for 11 years, earning recognition as a top Investor Relations Officer by Institutional Investor. Since 2018, Johnson has served as Lilly’s treasurer, leading initiatives to foster positive social and economic change for underrepresented groups within the financial community.
The successor to Johnson’s role will be announced at a later date.
About Lilly: Lilly is a pharmaceutical company dedicated to transforming scientific breakthroughs into life-improving therapies for individuals worldwide. With nearly 150 years of innovation, Lilly’s medicines impact over 51 million people globally. Through advancements in biotechnology, chemistry, and genetic medicine, Lilly’s scientists are tackling pressing health challenges, including diabetes care, obesity, Alzheimer’s disease, immune disorders, and cancer treatment. Committed to diversity and accessibility, Lilly conducts inclusive clinical trials and strives to make its medicines accessible and affordable. For more information, visit Lilly.com or follow Lilly on social media platforms.
Lilly Cautionary Statement Regarding Forward-Looking Statements: This press release includes forward-looking statements concerning leadership changes and Lilly’s strategic objectives. These statements reflect Lilly’s current beliefs and expectations, but there can be no assurance that these changes will achieve the desired outcomes or that Lilly will execute its strategy as intended. For a discussion of risks and uncertainties relevant to Lilly’s business, refer to Lilly’s recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly assumes no obligation to update forward-looking statements.
